JP2016516800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516800A5 JP2016516800A5 JP2016508192A JP2016508192A JP2016516800A5 JP 2016516800 A5 JP2016516800 A5 JP 2016516800A5 JP 2016508192 A JP2016508192 A JP 2016508192A JP 2016508192 A JP2016508192 A JP 2016508192A JP 2016516800 A5 JP2016516800 A5 JP 2016516800A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- egfr antibody
- fucose
- cancer
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13002106 | 2013-04-22 | ||
| EP13002106.6 | 2013-04-22 | ||
| EP13002108 | 2013-04-22 | ||
| EP13002108.2 | 2013-04-22 | ||
| PCT/EP2014/058118 WO2014173886A1 (en) | 2013-04-22 | 2014-04-22 | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016516800A JP2016516800A (ja) | 2016-06-09 |
| JP2016516800A5 true JP2016516800A5 (enExample) | 2017-05-25 |
Family
ID=50729450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016508192A Withdrawn JP2016516800A (ja) | 2013-04-22 | 2014-04-22 | フコシル化が少ない抗ｅｇｆｒ抗体による抗がん処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160068609A1 (enExample) |
| EP (1) | EP2989126A1 (enExample) |
| JP (1) | JP2016516800A (enExample) |
| KR (1) | KR20150144804A (enExample) |
| CN (1) | CN105229030A (enExample) |
| AU (1) | AU2014257650A1 (enExample) |
| BR (1) | BR112015025955A2 (enExample) |
| CA (1) | CA2908819A1 (enExample) |
| EA (1) | EA201591977A1 (enExample) |
| MX (1) | MX2015014773A (enExample) |
| SG (1) | SG11201507743XA (enExample) |
| WO (1) | WO2014173886A1 (enExample) |
| ZA (1) | ZA201507246B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| CN105820248A (zh) * | 2015-01-07 | 2016-08-03 | 上海张江生物技术有限公司 | 一种新型抗egfr单克隆抗体的制备方法及应用 |
| CN105399830B (zh) * | 2015-09-08 | 2019-11-19 | 北京天广实生物技术股份有限公司 | 抗egfr人源化单克隆抗体、其制备方法及用途 |
| EP3400248A4 (en) * | 2016-01-10 | 2019-09-04 | Sorrento Therapeutics, Inc. | IMPROVED SAFETY FOR THE TREATMENT OF CANCER WITH GLYCOSYLATED CHIMERIC ANTIBODY AGAINST EGFR |
| CN109195627B (zh) * | 2016-04-27 | 2022-09-09 | 株式会社绿十字 | 包含与表皮生长因子受体特异性结合的抗体作为活性成分的用于抑制癌症转移的药物组合物 |
| US11649291B2 (en) | 2016-05-24 | 2023-05-16 | Insmed Incorporated | Antibodies and methods of making same |
| CA3030422C (en) | 2016-07-13 | 2021-10-26 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
| KR101884614B1 (ko) | 2016-10-11 | 2018-08-02 | 신일제약주식회사 | Fab 단편 및 이의 용도 |
| CA3057758A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Pd-l1 and ta-muc1 antibodies |
| WO2018190719A2 (en) * | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| KR20200031571A (ko) * | 2017-05-29 | 2020-03-24 | 가마맵스 파마 | 암 연관 면역억제의 억제제 |
| WO2019222282A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| WO2020100969A1 (ja) * | 2018-11-14 | 2020-05-22 | 学校法人金沢医科大学 | びまん性胃がんを治療するための医薬組成物 |
| CN112300278A (zh) * | 2019-07-25 | 2021-02-02 | 上海交通大学 | 抗人egfr嵌合抗体及其制备方法和用途 |
| CN115698067A (zh) * | 2020-04-24 | 2023-02-03 | 美勒斯公司 | 使用结合lgr5及egfr的抗体的癌症治疗 |
| CN115960214A (zh) * | 2021-10-12 | 2023-04-14 | 中国科学院分子细胞科学卓越创新中心 | 中和呼吸道合胞病毒的全人抗体的设计及应用 |
| US20230250176A1 (en) * | 2022-02-09 | 2023-08-10 | Dragonfly Therapeutics, Inc. | Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| ATE440959T1 (de) | 2000-06-28 | 2009-09-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| ES2755976T3 (es) * | 2005-02-07 | 2020-04-24 | Roche Glycart Ag | Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas |
| PT2073842E (pt) | 2006-09-10 | 2015-04-07 | Glycotope Gmbh | Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos |
| WO2011101328A2 (en) * | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
| WO2012020059A1 (en) * | 2010-08-10 | 2012-02-16 | Glycotope Gmbh | Humanized egfr antibodies |
| CN103119064B (zh) * | 2010-08-10 | 2018-09-04 | 葛莱高托普有限公司 | Fab糖基化抗体 |
-
2014
- 2014-04-22 KR KR1020157033309A patent/KR20150144804A/ko not_active Withdrawn
- 2014-04-22 AU AU2014257650A patent/AU2014257650A1/en not_active Abandoned
- 2014-04-22 CA CA2908819A patent/CA2908819A1/en not_active Abandoned
- 2014-04-22 WO PCT/EP2014/058118 patent/WO2014173886A1/en not_active Ceased
- 2014-04-22 US US14/784,470 patent/US20160068609A1/en not_active Abandoned
- 2014-04-22 EA EA201591977A patent/EA201591977A1/ru unknown
- 2014-04-22 SG SG11201507743XA patent/SG11201507743XA/en unknown
- 2014-04-22 EP EP14724007.1A patent/EP2989126A1/en not_active Withdrawn
- 2014-04-22 MX MX2015014773A patent/MX2015014773A/es unknown
- 2014-04-22 JP JP2016508192A patent/JP2016516800A/ja not_active Withdrawn
- 2014-04-22 CN CN201480021328.XA patent/CN105229030A/zh active Pending
- 2014-04-22 BR BR112015025955A patent/BR112015025955A2/pt not_active IP Right Cessation
-
2015
- 2015-09-30 ZA ZA2015/07246A patent/ZA201507246B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021202413B2 (en) | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors | |
| Agustoni et al. | EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis | |
| JP7122357B2 (ja) | がんの治療のための方法、組成物、及びキット | |
| Henricks et al. | The use of combinations of monoclonal antibodies in clinical oncology | |
| JP2016516800A (ja) | フコシル化が少ない抗ｅｇｆｒ抗体による抗がん処置 | |
| JP7797875B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| TW201545759A (zh) | 用於治療非小細胞肺癌之抗ｂ７－ｈ１及抗ｃｔｌａ－４抗體 | |
| JP2022532490A5 (enExample) | ||
| Baldo | Monoclonal antibodies approved for cancer therapy | |
| Jarboe et al. | Therapeutic human monoclonal antibodies against cancer | |
| JP2020522562A5 (enExample) | ||
| JP2025060639A (ja) | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 | |
| EP3463453A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| JPWO2022270524A5 (enExample) | ||
| Ameri et al. | Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer | |
| CN104394887A (zh) | 采用具有低岩藻糖化的抗her2抗体的新治疗性疗法 | |
| JP2024536383A5 (enExample) | ||
| CN110177807B (zh) | 使用抗MUC1抗体和ErbB抑制剂的抗癌治疗 | |
| Wan et al. | Progress of immune checkpoint inhibitors in gastric cancer | |
| Ramanathan | Alternative dosing schedules for cetuximab: a role for biweekly administration? | |
| WO2022232503A1 (en) | Therapeutic and diagnostic methods and compositions for cancer | |
| CN116745322A (zh) | 使用抗岩藻糖基-gm1抗体的组合疗法 | |
| Rahman et al. | Monoclonal antibody: a cell specific immunotherapy to treat cancer | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| EP4660203A1 (en) | Pharmaceutical combination of anti-alpha v beta 3 antibody and anti-pd-1 antibody |